Translate Bio

The number of biotechs that are looking for partnerships while struggling for cash suggests there are plenty of reasonably priced candidates around but there are very few high-quality late-stage asset

Management consultants use gap analyses when helping biopharmaceutical companies target their therapeutic franchises’ opportunities relative to the unmet medical need and the competition. Sanofi’s vac

The number of biotechs that are looking for partnerships while struggling for cash suggests there are plenty of reasonably priced candidates around but there are very few high-quality late-stage asset

Just five months after bagging US rights to Provention Bio, Inc. 's type 1 diabetes therapy Tzield, Sanofi has decided it wants to buy the whole company and is prepared to pay a huge premium to do